Affomix
Corporation, a pioneer in the development of automated, high-throughput
monoclonal antibody selection technology, announced today that Kalgene
Pharmaceuticals Inc. has signed a commercial agreement to have Affomix
utilize its Y2HExpress™ technology to select
antibodies with potential diagnostic and therapeutic utility in breast
cancer. Kalgene
Pharmaceuticals Inc. is a private company focused on the development
of oncology therapeutics and companion diagnostics. The company's
portfolio of oncology products is at various stages in development, from
assay development to advanced clinical trials.
“Affomix is pleased to be working with Kalgene, a pharmaceutical company
executing a strategy of therapeutic development in conjunction with
companion diagnostic development”
Under the terms of the agreement Affomix will generate antibodies
against several proprietary targets selected by Kalgene. Affomix will
utilize its Y2HExpress™ technology for the
selection of single-chain antibodies with substantially increased
throughput, and specificity, over conventional Y2H and alternative
antibody selection methodologies. Financial terms of the service
agreement were not disclosed, nor were the financial milestones related
to diagnostic and therapeutic applications.
“After much diligence, Kalgene
chose Affomix
as the company to rapidly procure antibodies against our proprietary
targets”, said Dr. T. Nathan Yoganathan, President and CEO of Kalgene
Pharmaceuticals Inc. “Y2HExpress™ has the ability
to select antibodies at an unprecedented level of specificity, combined
with very favorable financial advantages,” Yoganathan continued.